(2r,6r)-hydroxynorketamine hydrochloride
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 11, 2021 (NCT04711005)
Timeline
Indications
Studied for
- Behavioral Symptoms · Phase 2
- Depression · Phase 2
- Depressive Disorder · Phase 2
- Depressive Disorder, Treatment-Resistant · Phase 2
- Excitatory Amino Acid Agents · Phase 2
- Ketamine · Phase 2
- Major Depressive Disorder · Phase 2
- Mental Disorders · Phase 2
- Molecular Mechanisms of Pharmacological Action · Phase 2
- Mood Disorders · Phase 2
- Neuralgia · Phase 1/Phase 2
- Neurotransmitter Agents · Phase 2
- Obsessive-Compulsive Disorder · Phase 1/Phase 2
- Physiological Effects of Drugs · Phase 2
- Suicide · Phase 2
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06575075 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | National Institutes of Health (NIH), Stanford University |
| NCT06511908 | Phase 2 | Nov 17, 2024 | National Institute of Mental Health (NIMH) |
| NCT05864053 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2024 | Department of Defense, Rush University |
| NCT04711005 | Phase 1 | Jan 11, 2021 | National Institute of Mental Health (NIMH) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | Government | 2 | 2 | 2 | 2021 |
| Department of Defense | Government | 1 | 0 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2024 |
| Rush University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1